Katie Dahlstrom
Hoofd Techniek/Wetenschap/O&O bij THESEUS PHARMACEUTICALS, INC.
Profiel
Katie Dahlstrom is currently the Vice President-Clinical Development Operations at Theseus Pharmaceuticals, Inc. Previously, she worked as the Senior Director-Clinical Operations at Agios Pharmaceuticals, Inc. She completed her undergraduate degree at Stonehill College, Inc. and her graduate degree at Boston University School of Medicine.
Actieve functies van Katie Dahlstrom
| Bedrijven | Functie | Begin |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Eerdere bekende functies van Katie Dahlstrom
| Bedrijven | Functie | Einde |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Katie Dahlstrom
| Stonehill College, Inc. | Undergraduate Degree |
| Boston University School of Medicine | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
